Somewhat Favorable Press Coverage Likely to Affect Albany Molecular Research (AMRI) Stock Price

Media headlines about Albany Molecular Research (NASDAQ:AMRI) have been trending somewhat positive recently, AlphaOne Sentiment Analysis reports. The research firm, a unit of Accern, identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Albany Molecular Research earned a media sentiment score of 0.18 on AlphaOne’s scale. AlphaOne also gave press coverage about the biotechnology company an impact score of 78 out of 100, indicating that recent media coverage is likely to have an effect on the stock’s share price in the near future.

Shares of Albany Molecular Research (NASDAQ:AMRI) traded down 0.12% during midday trading on Friday, reaching $17.31. 469,086 shares of the company’s stock were exchanged. Albany Molecular Research has a 1-year low of $12.51 and a 1-year high of $19.35. The company’s market capitalization is $720.17 million. The firm has a 50-day moving average of $15.90 and a 200-day moving average of $16.53.

Albany Molecular Research (NASDAQ:AMRI) last released its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. The business had revenue of $163.80 million for the quarter, compared to analysts’ expectations of $161.43 million. Albany Molecular Research had a positive return on equity of 7.25% and a negative net margin of 10.48%. The firm’s quarterly revenue was up 55.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.07 EPS. Equities analysts expect that Albany Molecular Research will post $1.15 earnings per share for the current fiscal year.

Separately, Morgan Stanley downgraded shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price objective for the company. in a report on Thursday, May 11th. They noted that the move was a valuation call.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

12 Month Chart for NASDAQ:AMRI

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply